Literature DB >> 30239757

Effects of Pitavastatin on Insulin Sensitivity and Liver Fat: A Randomized Clinical Trial.

Laurie R Braun1,2, Meghan N Feldpausch1, Natalia Czerwonka1, Julian Weiss1, Karen Branch3, Hang Lee4, Edgar L Martinez-Salazar5, Martin Torriani5, Craig A Sponseller6, Steven K Grinspoon1, Takara L Stanley1,2.   

Abstract

Context: 3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) are widely prescribed. Statins may have important metabolic effects on insulin sensitivity and liver fat, but limited studies have assessed these effects by using euglycemic hyperinsulinemic clamp, stable isotopes, and 1H magnetic resonance spectroscopy (MRS) for liver fat quantification. Objective: To study the effects of pitavastatin on hepatic fat and insulin sensitivity. Design: Six-month, double-blind, randomized, placebo-controlled trial. Setting: Academic clinical research center in Boston, Massachusetts. Participants: Overweight, insulin-resistant men aged 40 to 65 years who had not received statin therapy for ≥1 year. Interventions: Pitavastatin 4 mg or placebo daily. Outcome: The primary endpoints were changes in insulin sensitivity measured by euglycemic hyperinsulinemic clamp and liver fat measured by 1H MRS.
Results: Pitavastatin showed no effect on endogenous glucose production (ΔRa glucose 0.07 ± 0.07 vs 0.04 ± 0.07 mg/kg/min, pitavastatin vs placebo, P = 0.76) or insulin-stimulated glucose uptake during "low dose" (ΔM 0.1 ± 0.1 vs -0.3 ± 0.2 mg/kg/min, P = 0.11) and "high dose" (ΔM -0.5 ± 0.3 vs -0.7 ± 0.4 mg/kg/min, P = 0.70) euglycemic hyperinsulinemic clamps. There was also no effect of pitavastatin on fasting glucose, HbA1c, and 2-hour glucose after 75-g glucose challenge. There was also no change in liver fat fraction (-1 ± 1 vs -0 ± 1%, P = 0.56).
Conclusion: Compared with placebo, pitavastatin did not affect hepatic or whole-body insulin sensitivity, and it did not reduce liver fat.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30239757      PMCID: PMC6194811          DOI: 10.1210/jc.2018-01446

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  44 in total

1.  Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study.

Authors:  Hideyuki Hyogo; Tadashi Ikegami; Katsutoshi Tokushige; Etsuko Hashimoto; Kazuo Inui; Yasushi Matsuzaki; Hironori Tokumo; Fumiaki Hino; Susumu Tazuma
Journal:  Hepatol Res       Date:  2011-09-22       Impact factor: 4.288

2.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

3.  Effects of intensive pitavastatin therapy on glucose control in patients with non-ST elevation acute coronary syndrome.

Authors:  Yan-Bo Wang; Xiang-Hua Fu; Xin-Shun Gu; Wei-Ze Fan; Yun-Fa Jiang; Guo-Zhen Hao; Qing Miao; Jie Cao; Bing Fu; Yi Li
Journal:  Am J Cardiovasc Dis       Date:  2017-07-25

4.  Hydrogen-1 MR spectroscopy for measurement and diagnosis of hepatic steatosis.

Authors:  Patrick Georgoff; David Thomasson; Adeline Louie; Estee Fleischman; Lauren Dutcher; Haresh Mani; Shyamasundaran Kottilil; Caryn Morse; Lori Dodd; David Kleiner; Colleen Hadigan
Journal:  AJR Am J Roentgenol       Date:  2012-07       Impact factor: 3.959

5.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

Authors:  David Preiss; Sreenivasa Rao Kondapally Seshasai; Paul Welsh; Sabina A Murphy; Jennifer E Ho; David D Waters; David A DeMicco; Philip Barter; Christopher P Cannon; Marc S Sabatine; Eugene Braunwald; John J P Kastelein; James A de Lemos; Michael A Blazing; Terje R Pedersen; Matti J Tikkanen; Naveed Sattar; Kausik K Ray
Journal:  JAMA       Date:  2011-06-22       Impact factor: 56.272

Review 6.  Balancing Primary Prevention and Statin-Induced Diabetes Mellitus Prevention.

Authors:  Yogita Rochlani; Ajoe John Kattoor; Naga Venkata Pothineni; Raga Deepak Reddy Palagiri; Francesco Romeo; Jawahar L Mehta
Journal:  Am J Cardiol       Date:  2017-07-14       Impact factor: 2.778

7.  Breath-hold 1H-magnetic resonance spectroscopy for intrahepatic lipid quantification at 3 Tesla.

Authors:  Miriam A Bredella; Reza Hosseini Ghomi; Bijoy J Thomas; Hugue A Ouellette; Dushyant V Sahani; Karen K Miller; Martin Torriani
Journal:  J Comput Assist Tomogr       Date:  2010 May-Jun       Impact factor: 1.826

8.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

9.  A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

Authors:  Austin Nelson; Dawn M Torres; Ana E Morgan; Christopher Fincke; Stephen A Harrison
Journal:  J Clin Gastroenterol       Date:  2009 Nov-Dec       Impact factor: 3.062

10.  Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial.

Authors:  Jun-Bean Park; Ji-Hyun Jung; Yeonyee E Yoon; Hack-Lyong Kim; Seung-Pyo Lee; Hyung-Kwan Kim; Yong-Jin Kim; Goo-Yeong Cho; Dae-Won Sohn
Journal:  Trials       Date:  2017-10-27       Impact factor: 2.279

View more
  11 in total

1.  Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

Authors:  Takara L Stanley; Lindsay T Fourman; Meghan N Feldpausch; Julia Purdy; Isabel Zheng; Chelsea S Pan; Julia Aepfelbacher; Colleen Buckless; Andrew Tsao; Anela Kellogg; Karen Branch; Hang Lee; Chia-Ying Liu; Kathleen E Corey; Raymond T Chung; Martin Torriani; David E Kleiner; Colleen M Hadigan; Steven K Grinspoon
Journal:  Lancet HIV       Date:  2019-10-11       Impact factor: 12.767

2.  LDL subclass lipidomics in atherogenic dyslipidemia: effect of statin therapy on bioactive lipids and dense LDL.

Authors:  M John Chapman; Alexina Orsoni; Ricardo Tan; Natalie A Mellett; Anh Nguyen; Paul Robillard; Philippe Giral; Patrice Thérond; Peter J Meikle
Journal:  J Lipid Res       Date:  2020-04-15       Impact factor: 5.922

3.  Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach.

Authors:  Chris deFilippi; Mabel Toribio; Lai Ping Wong; Ruslan Sadreyev; Ida Grundberg; Kathleen V Fitch; Markella V Zanni; Janet Lo; Craig A Sponseller; Emmett Sprecher; Narges Rashidi; Melanie A Thompson; Diana Cagliero; Judith A Aberg; Laurie R Braun; Takara L Stanley; Hang Lee; Steven K Grinspoon
Journal:  J Infect Dis       Date:  2020-08-17       Impact factor: 5.226

Review 4.  Implications of pre-transplant sarcopenia and frailty in patients with non-alcoholic steatohepatitis and alcoholic liver disease.

Authors:  Joseph S Redman; Matt Kaspar; Puneet Puri
Journal:  Transl Gastroenterol Hepatol       Date:  2022-07-25

Review 5.  Is there a role of lipid-lowering therapies in the management of fatty liver disease?

Authors:  Ismini Tzanaki; Aris P Agouridis; Michael S Kostapanos
Journal:  World J Hepatol       Date:  2022-01-27

6.  Association of Non-alcoholic Fatty Liver Disease With Salt Intake and Dietary Diversity in Chinese Medical Examination Adults Aged 18-59 Years: A Cross-Sectional Study.

Authors:  Xiaofei Luo; Ying Li; Yi Zhou; Chun Zhang; Lijun Li; Yating Luo; Jiangang Wang; Yinglong Duan; Jianfei Xie
Journal:  Front Nutr       Date:  2022-07-12

7.  Effects of rosuvastatin on serum glucose and insulin in hyperuricemic rats.

Authors:  Dilidaer Xilifu; Zumulaiti Tuerxun; Buweiayixiemu Nuermaimaiti; Ayinu Aili; Nijiati Rehemu; Huiping Sun; Xiangyang Zhang
Journal:  BMC Pharmacol Toxicol       Date:  2022-09-05       Impact factor: 2.605

8.  Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease.

Authors:  Takara L Stanley; Lindsay T Fourman; Isabel Zheng; Colin M McClure; Meghan N Feldpausch; Martin Torriani; Kathleen E Corey; Raymond T Chung; Hang Lee; David E Kleiner; Colleen M Hadigan; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2021-01-23       Impact factor: 5.958

Review 9.  Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.

Authors:  Nirmala Tilija Pun; Chul-Ho Jeong
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-16

10.  Differential Diabetogenic Effect of Pitavastatin and Rosuvastatin, in vitro and in vivo.

Authors:  Yongin Cho; Hyangkyu Lee; Hyun Ki Park; Eun Yeong Choe; Hye Jin Wang; Ryeong-Hyeon Kim; Youjin Kim; Eun Seok Kang
Journal:  J Atheroscler Thromb       Date:  2019-09-13       Impact factor: 4.928

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.